Aveo Pharmaceuticals Stock News

Aveo Pharmaceuticals Inc (NASDAQ: AVEO ) will present new long-term progression-free survival (PFS) data from the Phase 3 TIVO-3 study in kidney cancer at the 2022 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium. The trial is evaluating Fotivda (tivozanib) to Bayer AG''s (OTC: BAYRY ) … Full story available on Benzinga.com

Five year follow-up data show FOTIVDA® (tivozanib) patients up to 5X more likely to experience long-term PFS compared to Nexavar® (sorafenib)

Five year follow-up data show FOTIVDA® (tivozanib) patients up to 5X more likely to experience long-term PFS compared to Nexavar® (sorafenib)

BOSTON, Feb. 03, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that members of its senior management team will

AVEO Pharmaceuticals Inc (AVEO) shares closed today at 0.5% above its 52 week low of $3.78, giving the company a market cap of $130M. The stock is currently down 19.0% year-to-date, down 52.6% over the past 12 months, and down 38.2% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 rose 0.6%. Trading Activity Trading volume this week was 53.5% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.3. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -3092.2% The company's stock price performance over the past 12 months lags the peer average by -5096.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

AVEO Pharmaceuticals Inc (AVEO) shares closed today at 0.5% above its 52 week low of $3.95, giving the company a market cap of $138M. The stock is currently down 14.1% year-to-date, down 46.3% over the past 12 months, and down 36.7% over the past five years. This week, the Dow Jones Industrial Average fell 1.4%, and the S&P 500 fell 1.6%. Trading Activity Trading volume this week was 28.2% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.3. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -1623.1% The company's stock price performance over the past 12 months lags the peer average by -1910.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

AVEO Pharmaceuticals Inc (AVEO) shares closed today at 1.0% above its 52 week low of $4.14, giving the company a market cap of $143M. The stock is currently down 10.9% year-to-date, down 44.3% over the past 12 months, and down 35.7% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 23.4% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.3. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 489.1% The company's stock price performance over the past 12 months lags the peer average by -988.8% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

BOSTON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today highlighted its recent progress and outlook for 2022.

AVEO Pharmaceuticals Inc (AVEO) shares closed today at 0.2% above its 52 week low of $4.80, giving the company a market cap of $166M. The stock is currently down 15.9% year-to-date, down 11.5% over the past 12 months, and down 14.2% over the past five years. This week, the Dow Jones Industrial Average rose 2.1%, and the S&P 500 rose 2.1%. Trading Activity Trading volume this week was 11.2% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.2. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -240.0% The company's stock price performance over the past 12 months lags the peer average by -190.4% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

BOSTON, Dec. 22, 2021 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that members of its senior management team wil

Related Stocks: KROS , CRNX , OPTN , SMLR , FOLD , MRUS , DTIL , AADI , NCNA , MGNX , SIOX , APTO , AVEO , EPIX , MCRB , CMLF , LUMO , KZR , CRDF ,

Equities analysts expect AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) to announce earnings of ($0.16) per share for the current quarter, Zacks reports. Three analysts have provided estimates for AVEO Pharmaceuticals earnings. The highest EPS estimate is ($0.10) and the lowest is ($0.23). AVEO Pharmaceuticals posted earnings per share of ($0.44) during the same quarter last year, which []

Equities analysts forecast that AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) will post $23.39 million in sales for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for AVEO Pharmaceuticals earnings, with estimates ranging from $22.80 million to $23.76 million. AVEO Pharmaceuticals reported sales of $890,000.00 in the same quarter last year, which []

Analysts predict that AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) will report earnings of ($0.16) per share for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for AVEO Pharmaceuticals earnings. The highest EPS estimate is ($0.10) and the lowest is ($0.23). AVEO Pharmaceuticals reported earnings per share of ($0.44) in the same quarter last []

In last trading session, AVEO Pharmaceuticals Inc. (NASDAQ:AVEO) saw 0.34 million shares changing hands with its beta currently measuring 1.10. Companys recent per share price level of $5.34 trading at -$0.38 or -6.64% at ring of the bell on the day assigns it a market valuation of $181.13M. That closing price of AVEOs stock is AVEO Pharmaceuticals Inc. (NASDAQ:AVEO) Shares Rebounded 7.3% From Their Lows But Can They Continue? Read More »